Advances in Proteomics and Metabolomics 2021

This online symposium took place on June 30, 2021
Brought to you by Technology Networks

Online Symposium Overview

The online symposium on “Advances in Proteomics and Metabolomics 2021” highlights the latest advances in proteomics and metabolomics research and their applications in modern medicine. This event from Technology Networks featured a collection of exclusive talks from leading scientists in the field, discussing their research and lending insights on the advances and challenges in this exciting space.

The insights offered by proteomic and metabolomic approaches are helping to shape our understanding of diseases, accelerate the development of novel clinical biomarkers and facilitate drug discovery. If you want to learn how proteomics and metabolomics insights are fundamental in our pursuit towards personalized medicine, and how Bruker is contributing to this check out our on-demand presentations from this event.

Latest Applications of 4D-Proteomics using the timsTOF Pro and recent developments in ultra-high sensitivity applications

Gary Kruppa, Ph.D., Vice President Proteomics at Bruker Daltonics Inc., and Managing Director of Bruker S.R.O., Billerica, MA, USA

Gary Kruppa serves as the Vice President for Proteomics at Bruker Daltonics Inc. He manages a growing global team of applications, field applications and applications development scientists, focused on developing new proteomics applications for the timsTOF Pro, and supporting customers and collaborators.  Dr. Kruppa earned his bachelor’s degree in chemistry at the University of Delaware and his Ph. D. in chemical physics at CalTech. Dr. Kruppa has been working with Bruker since 1991, where he first worked on the FTMS product line, later serving as Vice President for FTMS. From 2001 to 2004, Dr. Kruppa ran his own research lab at Sandia National Labs, where he and his team developed novel methods and reagents for chemical crosslinking of proteins for the study of protein structure. In 2004 he rejoined Bruker, where he served as Vice President for Business Development until 2014. From 2014 to 2016 Dr. Kruppa worked as CEO of MRM Proteomics Inc., to commercialize kits for quantitative MRM proteomics analysis of potential biomarkers. Dr. Kruppa returned to Bruker in 2016 to serve as Vice President for proteomics, where he helped launch the revolutionary timsTOF Pro QTOF Mass Spectrometer powered by the PASEF method.

Multimodal Imaging Mass Spectrometry: Advanced Technologies for Molecular Mapping of Biological Tissues   

Jeffrey Spraggins, Ph.D.,
Research Assistant Professor, Department of Biochemistry, Vanderbilt University, Nashville, TN, USA

Jeffrey Spraggins is a faculty member in the Departments of Cell & Developmental Biology, Biochemistry, and Chemistry, Director of the Biomolecular Multimodal Imaging Center (BIOMIC), and a member of the Mass Spectrometry Research Center at Vanderbilt University in Nashville, TN. His research focuses on the development of next-generation molecular imaging technologies and advanced applications for imaging mass spectrometry (IMS). One point of focus has been on developing high performance instrumentation to maximize spatial resolution, sensitivity, and molecular specificity for molecular imaging experiments. He has also been part of a team focused on multimodal image fusion. This work aims to create new imaging modalities that synergistically combine data from different imaging experiments (e.g. microscopy and IMS). Recently, his research group has begun to apply these advanced imaging technologies for the construction and analysis of 3-D multimodal molecular atlases. As part of the Human Biomolecular Atlas Program (HuBMAP, NIH), he is working on bringing together 3-D imaging mass spectrometry with a variety of in vivo and ex vivo imaging technologies to create new modalities of molecularly-informed biomedical imaging.


For Research Use Only. Not for use in clinical diagnostic procedures.